EGYPT – Alameda Healthcare Group (Alameda) has entered into a landmark memorandum of understanding (MoU) with Varian, a Siemens Healthineers company.

In a joint statement, Dr. Fahad Khater, Chairman of Alameda Healthcare Group said: “Our collaboration with Varian stands as a resounding testament to our commitment to elevating the standard of healthcare in Egypt.”

As part of the extended pact, the parties have agreed to establish an Alameda site as a reference center for Varian products in the Middle East and Africa.

This extended collaboration is aimed at facilitating knowledge transfer for clinical staff from various hospitals, both within and outside Egypt.

It is intended to see the establishment of an Alameda reference center for Varian products, the development of cutting-edge medical technologies, and a shared dedication to improving patient outcomes.

Through this partnership, Alameda seizes a unique opportunity to revolutionize cancer care in the country through cutting-edge technology, and in turn, resulting in improved patient outcomes and a healthier population,” stated Dr. Fahad Khater.

The strategic alliance marks a significant stride toward realizing the Egyptian healthcare group’s vision of a healthcare industry that sets new standards for excellence across Egypt and beyond.

This news comes after an MoU was signed between Siemens Healthineers and the Alameda Healthcare Group at Siemens Healthineers’ manufacturing premises in Forchheim, Germany.

The companies agreed to a technology roadmap that will see Siemens Healthineers install, replace, and maintain its state-of-the-art medical technology systems and equipment across Alameda’s medical facilities.

Notably, the signing of the memorandum of understanding between Alameda Healthcare Group and Varian took place at Varian’s headquarters in Palo Alto, the United States of America.

Commenting on this news, Laurent Amiel, President of Radiation Oncology Solutions in Europe, the Middle East, and Africa at Varian, outlined: “Varian is committed to enhancing care experience for both patients and clinicians and expanding access to high-quality treatment.”

The intended collaborative effort between Alameda Healthcare Group and Varian will be characterized by several key elements.

In line with a profound shared commitment to healthcare excellence, the two organizations are set to reshape the healthcare landscape, deliver innovative solutions, and transform the lives of countless individuals.

The MoU will see the two parties develop a specialized medical radiation oncology roadmap, ensuring the supply and maintenance of Varian products, including radiation oncology equipment.

Additionally, Alameda Healthcare Group and Varian will see the implementation of digital health solutions to streamline clinical operations, accompanied by comprehensive education and training programs.

This partnership will see the two organizations collaborate and develop various programs covering technical, clinical, and quality assurance aspects related to the Varian products.

Underlining the significance of the MoU with Alameda Healthcare Group, Laurent Amiel said: “This collaboration marks a significant step forward in our shared dedication to elevate cancer care, driven by innovations, education, and a shared vision of healthcare excellence.”

Additionally, the collaboration will encompass clinical pathway advisory services to enhance care delivery, support in the multistep process of a greenfield hospital design, and the creation of a luminary site program to advance Alameda’s vision of oncology care in Africa.

The collaboration between Alameda Healthcare Group and Varian marks a pivotal moment in the evolution of healthcare in Egypt, the Middle East, and the broader African region.

Together, we aim to improve the realm of cancer care, making a positive impact on countless individuals’ lives in these regions and beyond,” highlighted Laurent Amiel.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.